• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

    8/12/25 6:07:18 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZLAB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Zai Lab Limited

    (Name of Issuer)


    Ordinary shares, par value US $0.000006 per share

    (Title of Class of Securities)


    98887Q104

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    98887Q104


    1Names of Reporting Persons

    Qiming Corporate GP IV, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    66,329,320.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    66,329,320.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    66,329,320.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.97 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Note to Row (5) (7) and (9): As of the date of this 13G/A filing, Qiming Corporate GP IV, Ltd. is the general partner of Qiming Managing Directors Fund IV, L.P. and Qiming GP IV, L.P. Qiming Managing Directors Fund IV, L.P. holds approximately 3.06% of the equity interest of QM11 Limited. Qiming GP IV, L.P. is the general partner of Qiming Venture Partners IV, L.P., which holds approximately 96.94% of the equity interest of QM11 Limited. QM11 Limited is the owner of 66,329,320 Ordinary Shares, which is consisted of 1,268,000 ADSs and 53,649,320 ordinary shares. Note to Row (11): The percentage is calculated based upon an aggregate of 1,110,783,740 Ordinary Shares outstanding as of June 30, 2025, which is based on the information disclosed by the Issuer on July 7, 2025.


    SCHEDULE 13G

    CUSIP No.
    98887Q104


    1Names of Reporting Persons

    Qiming Managing Directors Fund IV, L.P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,030,208.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,030,208.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,030,208.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.18 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Row (6) (8) and (9): As of the date of this 13G/A filing, Qiming Managing Directors Fund IV, L.P. holds approximately 3.06% of the equity interest of QM11 Limited, which is the owner of 66,329,320 Ordinary Shares (in the form of 1,268,000 ADSs and 53,649,320 ordinary shares). Note to Row (11): The percentage is calculated based upon an aggregate of 1,110,783,740 Ordinary Shares outstanding as of June 30, 2025, which is based on the information disclosed by the Issuer on July 7, 2025.


    SCHEDULE 13G

    CUSIP No.
    98887Q104


    1Names of Reporting Persons

    Qiming GP IV, L.P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    64,299,112.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    64,299,112.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    64,299,112.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.79 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Row (6) (8) and (9): As of the date of this 13G/A filing, Qiming GP IV, L.P. is the general partner of Qiming Venture Partners IV, L.P., which owns approximately 96.94% of the equity interest of QM11 Limited, which is the owner of 66,329,320 Ordinary Shares (in the form of 1,268,000 ADSs and 53,649,320 ordinary shares). Note to Row (11): The percentage is calculated based upon an aggregate of 1,110,783,740 Ordinary Shares outstanding as of June 30, 2025, which is based on the information disclosed by the Issuer on July 7, 2025.


    SCHEDULE 13G

    CUSIP No.
    98887Q104


    1Names of Reporting Persons

    Qiming Venture Partners IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    64,299,112.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    64,299,112.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    64,299,112.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.79 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Row (6) (8) and (9): As of the date of this 13G/A filing, Qiming Venture Partners IV, L.P. holds approximately 96.94% of the equity interest of QM11 Limited, which is the owner of 66,329,320 Ordinary Shares (in the form of 1,268,000 ADSs and 53,649,320 ordinary shares). Note to Row (11): The percentage is calculated based upon an aggregate of 1,110,783,740 Ordinary Shares outstanding as of June 30, 2025, which is based on the information disclosed by the Issuer on July 7, 2025.


    SCHEDULE 13G

    CUSIP No.
    98887Q104


    1Names of Reporting Persons

    QM11 Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    HONG KONG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    66,329,320.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    66,329,320.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    66,329,320.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.97 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Note to Row (11): The percentage is calculated based upon an aggregate of 1,110,783,740 Ordinary Shares outstanding as of June 30, 2025, which is based on the information disclosed by the Issuer on July 7, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Zai Lab Limited
    (b)Address of issuer's principal executive offices:

    4560 Jinke Road, Bldg.1, 4F, Pudong, Shanghai, China 201210 and 314 Main Street 4th Floor, Suite 100 Cambridge, MA, USA 02142
    Item 2. 
    (a)Name of person filing:

    Qiming Corporate GP IV, Ltd. Qiming Managing Directors Fund IV, L.P. Qiming GP IV, L.P. Qiming Venture Partners IV, L.P. QM11 Limited
    (b)Address or principal business office or, if none, residence:

    The registered address of each of Qiming Corporate GP IV, Ltd., Qiming Managing Directors Fund IV, L.P., Qiming GP IV, L.P. and Qiming Venture Partners IV, L.P. is M&C Corporate Services Limited, P.O. Box309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands. The registered address of QM11 Limited is Units 4205-06, 42nd Floor, Gloucester Tower, the Landmark, 15 Queen's Road Central, Hong Kong.
    (c)Citizenship:

    Qiming Corporate GP IV, Ltd., Qiming Managing Directors Fund IV, L.P., Qiming GP IV, L.P. and Qiming Venture Partners IV, L.P. are organized in Cayman Islands. QM11 Limited is a company organized in Hong Kong.
    (d)Title of class of securities:

    Ordinary shares, par value US $0.000006 per share
    (e)CUSIP No.:

    98887Q104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information set forth in Row (9) of the cover page for each of the Reporting Person is incorporated herein by reference.
    (b)Percent of class:

    The information set forth in Row (11) of the cover page for each of the Reporting Person is incorporated herein by reference.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information set forth in Row (5) of the cover page for each of the Reporting Person is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information set forth in Row (6) of the cover page for each of the Reporting Person is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information set forth in Row (7) of the cover page for each of the Reporting Person is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information set forth in Row (8) of the cover page for each of the Reporting Person is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Qiming Corporate GP IV, Ltd.
     
    Signature:/s/ Holan Lam
    Name/Title:Holan Lam/Authorized Signatory
    Date:08/12/2025
     
    Qiming Managing Directors Fund IV, L.P
     
    Signature:/s/ Holan Lam
    Name/Title:Holan Lam/Authorized Signatory
    Date:08/12/2025
     
    Qiming GP IV, L.P
     
    Signature:/s/ Holan Lam
    Name/Title:Holan Lam/Authorized Signatory
    Date:08/12/2025
     
    Qiming Venture Partners IV, L.P.
     
    Signature:/s/ Holan Lam
    Name/Title:Holan Lam/Authorized Signatory
    Date:08/12/2025
     
    QM11 Limited
     
    Signature:/s/ Holan Lam
    Name/Title:Holan Lam/Authorized Signatory
    Date:08/12/2025
    Exhibit Information

    Exhibit A Joint Filing Agreement dated February 13, 2019 https://www.sec.gov/Archives/edgar/data/1704292/000095010319001958/dp102255_sc13ga-zai.htm

    Get the next $ZLAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZLAB

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    3/3/2025$29.00 → $36.10Buy → Neutral
    BofA Securities
    12/14/2023$47.50Overweight
    Morgan Stanley
    8/10/2023$70.00Overweight
    Cantor Fitzgerald
    3/2/2022$194.00 → $102.00Outperform
    SVB Leerink
    1/21/2022$64.00Outperform
    Macquarie
    12/15/2021$189.00 → $136.00Overweight
    JP Morgan
    11/11/2021$222.00 → $217.00Buy
    Citigroup
    More analyst ratings

    $ZLAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    5/15/24 4:03:12 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    3/4/24 4:28:34 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    12/18/23 5:08:48 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

    Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunities for the NMPA to prioritize the allocation of review resources to expedite the regulatory review and approval process. "We are excited that TTFields has been granted the Innovative Medical Device Designation, a status that offers expedited r

    8/19/25 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Establishes Oncology Scientific Advisory Board

    - Newly formed Advisory Board comprises world-class leaders in oncology to support advancement of Zai Lab's robust oncology products and pipeline Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is comprised of distinguished oncology leaders and will support the advancement of the Company's robust oncology products and pipeline, including multiple internally developed investigational therapies. "We are honored to bring together this esteemed group of oncology leaders who will support our continued development and advancement of innovative treatment options for patients globally," said R

    8/13/25 11:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

    Total revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million VYVGART reached record patient utilization in the second quarter; updated national guidelines elevate VYVGART's role as a treatment for both acute and maintenance gMG Operating loss improved by 28% year-over-year to $54.9 million for the second quarter of 2025, and by 37% to $34.2 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025 ZL-1310 (DLL3 ADC) data presented at ASCO 2025 showed a 67% ORR across all doses (n=33) and 79% at 1.6mg/kg (n=14) in 2L ES-SCLC, with a differentiate

    8/7/25 6:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Zai Lab with a new price target

    Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00

    3/7/25 8:00:31 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab downgraded by BofA Securities with a new price target

    BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously

    3/3/25 7:38:45 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Zai Lab with a new price target

    Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50

    12/14/23 7:54:36 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Smiley Joshua L converted options into 15,900 units of American Depositary Shares and sold $240,643 worth of American Depositary Shares (6,641 units at $36.24), increasing direct ownership by 14% to 76,604 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    8/19/25 4:40:23 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Edmondson Frazor Titus Iii converted options into 4,850 units of American Depositary Shares and sold $68,232 worth of American Depositary Shares (1,883 units at $36.24), increasing direct ownership by 8% to 42,065 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    8/19/25 4:40:04 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Chen Yajing converted options into 1,250 units of American Depositary Shares and sold $50,932 worth of American Depositary Shares (1,438 units at $35.42), decreasing direct ownership by 1% to 16,720 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    8/18/25 4:29:46 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Zai Lab Limited

    SCHEDULE 13G - Zai Lab Ltd (0001704292) (Subject)

    8/14/25 8:14:51 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Zai Lab Limited

    144 - Zai Lab Ltd (0001704292) (Subject)

    8/12/25 4:45:11 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

    SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

    8/12/25 10:34:26 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Financials

    Live finance-specific insights

    View All

    Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

    Total revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million VYVGART reached record patient utilization in the second quarter; updated national guidelines elevate VYVGART's role as a treatment for both acute and maintenance gMG Operating loss improved by 28% year-over-year to $54.9 million for the second quarter of 2025, and by 37% to $34.2 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025 ZL-1310 (DLL3 ADC) data presented at ASCO 2025 showed a 67% ORR across all doses (n=33) and 79% at 1.6mg/kg (n=14) in 2L ES-SCLC, with a differentiate

    8/7/25 6:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

    - Company to host conference call and webcast on August 7, 2025, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its second quarter 2025 financial results and provide recent corporate updates on August 7, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred):

    7/10/25 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

    - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc

    6/2/25 7:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zai Lab Limited

    SC 13G - Zai Lab Ltd (0001704292) (Subject)

    11/14/24 11:11:39 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

    SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

    11/8/24 10:52:38 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

    SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

    6/6/24 9:54:34 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Leadership Updates

    Live Leadership Updates

    View All

    Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

      Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

    6/11/24 4:05:00 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Appoints Michel Vounatsos To Its Board of Directors

    SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt

    1/9/23 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

    SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog

    1/3/23 8:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care